GSEP
CRDF icon

Golden State Equity Partners’s Cardiff Oncology CRDF Stock Holding History

Golden State Equity Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,500
Closed -$39.7K – 619
2026
Q1 		$39.7K Hold
24,500
– – ﹤0.01% 932
2025
Q4 		$68.8K Buy
+24,500
New +$56.9K 0.01% 489

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Golden State Equity Partners's CRDF Position: Q2 2026 in Review

Golden State Equity Partners sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 24,500 shares — an estimated $39.7K sold.

Golden State Equity Partners first reported a position in CRDF in Q4 2025 and held it in 2 quarters. The position peaked at $68.8K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Golden State Equity Partners reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 24,500 Cardiff Oncology shares in Q2 2026, an estimated $39.7K.
  • Golden State Equity Partners first reported a position in Cardiff Oncology in Q4 2025 and held it in 2 quarters.
  • Golden State Equity Partners's Cardiff Oncology position peaked at $68.8K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.